Olema Pharmaceuticals, INC Form 4 insider transactions

Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc., sold 25,000 shares of common stock on July 23, 2026.

Director Prakash Raman was granted stock options for 27,061 shares of Olema Pharmaceuticals common stock.

Olema Pharmaceuticals' Chief Legal Officer, Shawnte Mitchell, exercised stock options and subsequently sold a total of 40,000 shares of common stock.

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, was granted 356,250 stock options, including performance-based awards, on February 2, 2026.

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, was granted 356,250 stock options, including performance-based awards, effective February 2, 2026.

Olema Pharmaceuticals, Inc. has granted its Chief Legal Officer, Shawnte Mitchell, 276,250 stock options with a $25.65 exercise price, including performance-based awards.

Olema Pharmaceuticals' President and CEO, Sean Bohen, was granted 1,125,000 stock options, including performance-based awards, effective February 2, 2026.

Olema Pharmaceuticals Director Cyrus Harmon sold 10,000 shares of common stock for $26.88 per share under a pre-arranged trading plan.

Olema Pharmaceuticals Director Cyrus Harmon sold 3,489 shares of common stock at an average price of $29.12 under a pre-arranged 10b5-1 plan.

Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, reported two sales of common stock totaling 103,822 shares in January 2026.

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, exercised stock options and subsequently sold a significant number of common shares.

Olema Pharmaceuticals' President and CEO, Sean Bohen, reported a gift of 8,500 shares of common stock to a charitable donor advised fund.

Olema Pharmaceuticals Director Cyrus Harmon sold 2,881 shares of common stock for $28.53 per share under a pre-arranged Rule 10b5-1 trading plan.

Olema Pharmaceuticals Director Ian T. Clark exercised stock options and immediately sold all resulting shares on December 19, 2025.

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, reported multiple sales and a gift of common stock, alongside an update to his beneficial ownership.

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, exercised stock options and subsequently sold a significant number of shares in late December 2025 under a pre-arranged trading plan.

Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, transferred 75,000 shares of common stock as a bona fide gift to a family trust.

Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, gifted 225,000 shares of common stock to a family trust.

Olema Pharmaceuticals Director Andrew Rappaport exercised stock options and subsequently gifted the acquired shares to a family foundation.

Olema Pharmaceuticals Director Cyrus Harmon reported multiple sales of common stock totaling 25,000 shares in mid-September 2025, executed under a Rule 10b5-1 plan.

BVF Partners L.P. and its affiliated entities, along with Mark N. Lampert, have filed a Form 4 detailing their substantial beneficial ownership in Olema Pharmaceuticals, Inc., including common stock, pre-funded warrants, and newly acquired stock options.

Olema Pharmaceuticals, Inc. Director Yi Larson was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting, as disclosed in a recent SEC Form 4 filing.

Olema Pharmaceuticals, Inc. Director J. Scott Garland was granted 24,150 stock options with an exercise price of $4.08, aligning his interests with shareholders.

Olema Pharmaceuticals Director Sandra Horning has acquired 24,150 stock options with an exercise price of $4.08, vesting over 12 months or by the next annual meeting.

Olema Pharmaceuticals, Inc. Director Ian T. Clark was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting.

Olema Pharmaceuticals, Inc. Director Gorjan Hrustanovic was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting.

Olema Pharmaceuticals, Inc. Director and 10% Owner, Graham G. Walmsley, was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months.

Olema Pharmaceuticals, Inc. Director Cyrus Harmon was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or by the next annual meeting.

Olema Pharmaceuticals, Inc. Director Cynthia M. Butitta was granted 24,150 stock options with an exercise price of $4.08 per share, vesting over 12 months.

Olema Pharmaceuticals Director Andrew Rappaport was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting.